<?xml version='1.0' encoding='utf-8'?>
<document id="31571146"><sentence text="Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies."><entity charOffset="35-47" id="DDI-PubMed.31571146.s1.e0" text="Darolutamide" /></sentence><sentence text="Darolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC)"><entity charOffset="0-12" id="DDI-PubMed.31571146.s2.e0" text="Darolutamide" /><entity charOffset="24-32" id="DDI-PubMed.31571146.s2.e1" text="androgen" /><pair ddi="false" e1="DDI-PubMed.31571146.s2.e0" e2="DDI-PubMed.31571146.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31571146.s2.e0" e2="DDI-PubMed.31571146.s2.e1" /></sentence><sentence text=" Accordingly, the drug-drug interaction (DDI) potential of darolutamide was investigated in both nonclinical and clinical studies"><entity charOffset="59-71" id="DDI-PubMed.31571146.s3.e0" text="darolutamide" /></sentence><sentence text="" /><sentence text="In vitro studies were performed to determine the potential for darolutamide to be a substrate, inducer or inhibitor for cytochrome P450 (CYP) isoforms, other metabolizing enzymes and drug transporters"><entity charOffset="63-75" id="DDI-PubMed.31571146.s5.e0" text="darolutamide" /></sentence><sentence text=" A phase I drug-interaction study in healthy volunteers evaluated the impact of co-administering rifampicin [CYP3A4 and P-glycoprotein (P-gp) inducer] and itraconazole [CYP3A4, P-gp and breast cancer resistance protein (BCRP) inhibitor] on the pharmacokinetics of darolutamide"><entity charOffset="97-107" id="DDI-PubMed.31571146.s6.e0" text="rifampicin" /><entity charOffset="155-167" id="DDI-PubMed.31571146.s6.e1" text="itraconazole" /><entity charOffset="264-276" id="DDI-PubMed.31571146.s6.e2" text="darolutamide" /><pair ddi="false" e1="DDI-PubMed.31571146.s6.e0" e2="DDI-PubMed.31571146.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31571146.s6.e0" e2="DDI-PubMed.31571146.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31571146.s6.e0" e2="DDI-PubMed.31571146.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31571146.s6.e1" e2="DDI-PubMed.31571146.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31571146.s6.e1" e2="DDI-PubMed.31571146.s6.e2" /></sentence><sentence text=" Two further phase I studies assessed the impact of co-administering oral darolutamide on the pharmacokineticsÂ of midazolam (sensitive CYP3A4 substrate) and dabigatran etexilate (P-gp substrate) and the impact on the pharmacokinetics of co-administered rosuvastatin [a substrate for BCRP, organic anion-transporting polypeptide (OATP)1B1, OATP1B3 and organic anion transporter (OAT)3]"><entity charOffset="74-86" id="DDI-PubMed.31571146.s7.e0" text="darolutamide" /><entity charOffset="114-123" id="DDI-PubMed.31571146.s7.e1" text="midazolam" /><entity charOffset="157-177" id="DDI-PubMed.31571146.s7.e2" text="dabigatran etexilate" /><entity charOffset="253-265" id="DDI-PubMed.31571146.s7.e3" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31571146.s7.e0" e2="DDI-PubMed.31571146.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31571146.s7.e0" e2="DDI-PubMed.31571146.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31571146.s7.e0" e2="DDI-PubMed.31571146.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31571146.s7.e0" e2="DDI-PubMed.31571146.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31571146.s7.e1" e2="DDI-PubMed.31571146.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31571146.s7.e1" e2="DDI-PubMed.31571146.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31571146.s7.e1" e2="DDI-PubMed.31571146.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31571146.s7.e2" e2="DDI-PubMed.31571146.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31571146.s7.e2" e2="DDI-PubMed.31571146.s7.e3" /></sentence><sentence text="" /><sentence text="In vitro, darolutamide was predominantly metabolized via oxidative biotransformation catalyzed by CYP3A4 and was identified as a substrate for P-gp and BCRP"><entity charOffset="10-22" id="DDI-PubMed.31571146.s9.e0" text="darolutamide" /></sentence><sentence text=" The enzymatic activity of nine CYP isoforms was not inhibited or slightly inhibited in vitro with darolutamide, and a rank order and mechanistic static assessment indicated that risk of clinically relevant DDIs via CYP inhibition is very low"><entity charOffset="99-111" id="DDI-PubMed.31571146.s10.e0" text="darolutamide" /></sentence><sentence text=" In vitro, darolutamide exhibited no relevant induction of CYP1A2 or CYP2B6 activity"><entity charOffset="11-23" id="DDI-PubMed.31571146.s11.e0" text="darolutamide" /></sentence><sentence text=" Inhibition of BCRP-, P-gp-, OAT3-, MATE1-, MATE2-K-, OATP1B1- and OATP1B3-mediated transport was observed in vitro" /><sentence text=" Phase I data showed that darolutamide exposure increased 1"><entity charOffset="26-38" id="DDI-PubMed.31571146.s13.e0" text="darolutamide" /></sentence><sentence text="75-fold with co-administered itraconazole and decreased by 72% with rifampicin"><entity charOffset="29-41" id="DDI-PubMed.31571146.s14.e0" text="itraconazole" /><entity charOffset="68-78" id="DDI-PubMed.31571146.s14.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.31571146.s14.e0" e2="DDI-PubMed.31571146.s14.e0" /><pair ddi="false" e1="DDI-PubMed.31571146.s14.e0" e2="DDI-PubMed.31571146.s14.e1" /></sentence><sentence text=" Co-administration of darolutamide with CYP3A4/P-gp substrates showed no effect or only minor effects"><entity charOffset="22-34" id="DDI-PubMed.31571146.s15.e0" text="darolutamide" /></sentence><sentence text=" Rosuvastatin exposure increased 5"><entity charOffset="1-13" id="DDI-PubMed.31571146.s16.e0" text="Rosuvastatin" /></sentence><sentence text="2-fold with darolutamide because of BCRP and probably also OATPB1/OATPB3 inhibition"><entity charOffset="12-24" id="DDI-PubMed.31571146.s17.e0" text="darolutamide" /></sentence><sentence text="" /><sentence text="Darolutamide has a low potential for clinically relevant DDIs with drugs that are substrates for CYP or P-gp; increased exposure of BCRP and probably OATP substrates was the main interaction of note"><entity charOffset="0-12" id="DDI-PubMed.31571146.s19.e0" text="Darolutamide" /></sentence><sentence text="" /></document>